Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 7010196, 9 pages
https://doi.org/10.1155/2018/7010196
Review Article

Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future

1Optics Group, Department of Human Protein Sciences, University Medical Center, Geneva, Switzerland
2Department of Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland

Correspondence should be addressed to Natacha Turck; hc.eginu@kcrut.ahcatan and Mehrad Hamédani; hc.2af@inademah.darhem

Received 19 September 2017; Revised 21 December 2017; Accepted 30 January 2018; Published 15 March 2018

Academic Editor: Marco E. M. Peluso

Copyright © 2018 Natacha Turck et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. R. Monteiro, A. C. P. Gonçalves, and A. M. P. S. Bezerra, “Isolated primary amyloidosis of the inferior rectus muscle mimicking Graves’ orbitopathy,” Einstein, vol. 14, no. 4, pp. 553–556, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Kamminga, N. M. Jansonius, J. W. Pott, and T. P. Links, “Unilateral proptosis: the role of medical history,” The British Journal of Ophthalmology, vol. 87, no. 3, pp. 370-371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. C. P. Goncalves, E. M. Gebrim, and M. L. Monteiro, “Imaging studies for diagnosing Graves’ orbitopathy and dysthyroid optic neuropathy,” Clinics, vol. 67, no. 11, pp. 1327–1334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. C. Goncalves, P. G. Costa, and M. L. Monteiro, “Inferior rectus muscle metastasis as a presenting sign of renal cell carcinoma: case report,” Arquivos Brasileiros de Oftalmologia, vol. 69, no. 3, pp. 435–438, 2006. View at Publisher · View at Google Scholar
  5. A. Zafar and D. R. Jordan, “Enlarged extraocular muscles as the presenting feature of acromegaly,” Ophthalmic Plastic and Reconstructive Surgery, vol. 20, no. 4, pp. 334–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. C. P. Gonçalves, R. B. . C. Moritz, and M. L. R. Monteiro, “Primary localized amyloidosis presenting as diffuse amorphous calcified mass in both orbits: case report,” Arquivos Brasileiros de Oftalmologia, vol. 74, no. 5, pp. 374–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Lacey, W. Chang, and J. Rootman, “Nonthyroid causes of extraocular muscle disease,” Survey of Ophthalmology, vol. 44, no. 3, pp. 187–213, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. G. E. Holmstrom and K. G. Nyman, “Primary orbital amyloidosis localised to an extraocular muscle,” The British Journal of Ophthalmology, vol. 71, no. 1, pp. 32-33, 1987. View at Publisher · View at Google Scholar
  9. N. Boddu, M. Jumani, V. Wadhwa, G. Bajaj, and F. Faas, “Not all orbitopathy is Graves’: discussion of cases and review of literature,” Frontiers in Endocrinology, vol. 8, p. 184, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Neto, F. C. Denardi, M. A. Tambascia et al., “Orbital lymphoma mimicking ophthalmopathy in a patient with Graves’,” The American Journal of the Medical Sciences, vol. 344, no. 5, pp. 418–421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Dutta, A. Ahuja, and C. Selvan, “Immunoglobulin G4 related thyroid disorders: diagnostic challenges and clinical outcomes,” Endokrynologia Polska, vol. 67, no. 5, pp. 520–524, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Bartalena and L. Chiovato, “Graves’-like orbitopathy: do not forget IgG4-related disease,” Journal of Endocrinological Investigation, vol. 37, no. 12, pp. 1233–1235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. F. F. Rundle and C. W. Wilson, “Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy,” Clinical Science, vol. 5, no. 3-4, pp. 177–194, 1945. View at Google Scholar
  14. F. F. Rundle, “Management of exophthalmos and related ocular changes in Graves’ disease,” Metabolism, vol. 6, no. 1, pp. 36–48, 1957. View at Google Scholar
  15. G. B. Bartley, “Rundle and his curve,” Archives of Ophthalmology, vol. 129, no. 3, pp. 356–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Maheshwari and E. Weis, “Thyroid associated orbitopathy,” Indian Journal of Ophthalmology, vol. 60, no. 2, pp. 87–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Saraci and A. Treta, “Ocular changes and approaches of ophthalmopathy in Basedow – Graves- Parry- Flajani disease,” Maedica, vol. 6, no. 2, pp. 146–152, 2011. View at Google Scholar
  18. M. Hamedani and A. Oberic, “Thyroid associated orbitopathy: from diagnosis to treatment,” Revue Medicale Suisse, vol. 9, no. 368, pp. 66–71, 2013. View at Google Scholar
  19. R. S. Bahn, “Graves’ ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–738, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Menconi, M. A. Profilo, M. Leo et al., “Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited,” Thyroid, vol. 24, no. 1, pp. 60–66, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. W. M. Wiersinga, T. Smit, R. van der Gaag, and L. Koornneef, “Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease,” Journal of Endocrinological Investigation, vol. 11, no. 8, pp. 615–619, 1988. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Bartalena, L. Baldeschi, A. Dickinson et al., “Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO,” European Journal of Endocrinology, vol. 158, no. 3, pp. 273–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. C. Matthews and A. A. Syed, “The role of TSH receptor antibodies in the management of Graves’ disease,” European Journal of Internal Medicine, vol. 22, no. 3, pp. 213–216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. P. Mourits, L. Koornneef, W. M. Wiersinga, M. F. Prummel, A. Berghout, and R. van der Gaag, “Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach,” The British Journal of Ophthalmology, vol. 73, no. 8, pp. 639–644, 1989. View at Publisher · View at Google Scholar · View at Scopus
  25. S. C. Werner, “Modification of the classification of the eye changes of Graves’ disease,” American Journal of Ophthalmology, vol. 83, no. 5, pp. 725–727, 1977. View at Publisher · View at Google Scholar · View at Scopus
  26. P. J. Dolman and J. Rootman, “VISA classification for Graves orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 22, no. 5, pp. 319–324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. The European Group on Graves’ Orbitopathy (EUGOGO), W. M. Wiersinga, P. Perros et al., “Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers,” European Journal of Endocrinology, vol. 155, no. 3, pp. 387–389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. N. McCoy, D. S. Kim, E. F. Gillespie, S. J. Atkins, T. J. Smith, and R. S. Douglas, “Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R+ T cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 7, pp. E1294–E1299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Marcocci and M. Marino, “Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 26, no. 3, pp. 325–337, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. V. Perez-Moreiras, A. Alvarez-Lopez, and E. C. Gomez, “Treatment of active corticosteroid-resistant Graves’ orbitopathy,” Ophthalmic Plastic and Reconstructive Surgery, vol. 30, no. 2, pp. 162–167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. T. J. Smith, G. J. Kahaly, D. G. Ezra et al., “Teprotumumab for thyroid-associated ophthalmopathy,” The New England Journal of Medicine, vol. 376, no. 18, pp. 1748–1761, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Wang and T. J. Smith, “Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy,” Investigative Ophthalmology & Visual Science, vol. 55, no. 3, pp. 1735–1748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. T. J. Smith, “TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy,” Nature Reviews Endocrinology, vol. 11, no. 3, pp. 171–181, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Tramontano, G. W. Cushing, A. C. Moses, and S. H. Ingbar, “Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG,” Endocrinology, vol. 119, no. 2, pp. 940–942, 1986. View at Publisher · View at Google Scholar · View at Scopus
  35. T. J. Smith, “TSHR as a therapeutic target in Graves’ disease,” Expert Opinion on Therapeutic Targets, vol. 21, no. 4, pp. 427–432, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Ock, J. Ahn, S. H. Lee et al., “IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter,” The FASEB Journal, vol. 27, no. 12, pp. 4899–4908, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. T. J. Smith and J. A. M. J. L. Janssen, “Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy,” Frontiers in Endocrinology, vol. 7, p. 167, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. C. C. Krieger, R. F. Place, C. Bevilacqua et al., “TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 6, pp. 2340–2347, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. K. C. Cheng, C. T. Hung, K. Y. Cheng et al., “Proteomic surveillance of putative new autoantigens in thyroid orbitopathy,” The British Journal of Ophthalmology, vol. 99, no. 11, pp. 1571–1576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. G. M. Lehmann, T. M. Garcia-Bates, T. J. Smith, S. E. Feldon, and R. P. Phipps, “Regulation of lymphocyte function by PPARγ: relevance to thyroid eye disease-related inflammation,” PPAR Research, vol. 2008, Article ID 895901, 12 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Khong, A. A. McNab, P. R. Ebeling, J. E. Craig, and D. Selva, “Pathogenesis of thyroid eye disease: review and update on molecular mechanisms,” The British Journal of Ophthalmology, vol. 100, no. 1, pp. 142–150, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Kahaly, G. Forster, and C. Hansen, “Glycosaminoglycans in thyroid eye disease,” Thyroid, vol. 8, no. 5, pp. 429–432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Zhao, Y. Deng, P. Gu et al., “Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy,” Experimental Eye Research, vol. 107, pp. 65–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Pérez-López, M. Sales-Sanz, G. Rebolleda et al., “Retrobulbar ocular blood flow changes after orbital decompression in Graves’ ophthalmopathy measured by color Doppler imaging,” Investigative Ophthalmology & Visual Science, vol. 52, no. 8, pp. 5612–5617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. Biomarkers Definitions Working Group, “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Eckstein, J. Esser, K. Mann, and M. Schott, “Clinical value of TSH receptor antibodies measurement in patients with Graves’ orbitopathy,” Pediatric Endocrinology Reviews, vol. 7, Supplement 2, pp. 198–203, 2010. View at Google Scholar
  47. M. Lantz, T. Planck, P. Asman, and B. Hallengren, “Increased TRAb and/or low anti-TPO titers at diagnosis of Graves’ disease are associated with an increased risk of developing ophthalmopathy after onset,” Experimental and Clinical Endocrinology & Diabetes, vol. 122, no. 2, pp. 113–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. J. H. Lee, S. H. Park, D. G. Koh, and B. K. Suh, “Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves’ ophthalmopathy,” World Journal of Pediatrics, vol. 10, no. 2, pp. 155–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. M. N. Gerding, J. W. C. van der Meer, M. Broenink, O. Bakker, W. M. Wiersinga, and M. F. Prummel, “Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy,” Clinical Endocrinology, vol. 52, no. 3, pp. 267–271, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. X. G. Vos, N. Smit, E. Endert, J. G. P. Tijssen, and W. M. Wiersinga, “Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves’ hyperthyroidism: a prospective study,” Clinical Endocrinology, vol. 69, no. 2, pp. 311–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. S. D. Lytton, K. A. Ponto, M. Kanitz, N. Matheis, L. D. Kohn, and G. J. Kahaly, “A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 5, pp. 2123–2131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. H. B. Burch and L. Wartofsky, “Graves’ ophthalmopathy: current concepts regarding pathogenesis and management,” Endocrine Reviews, vol. 14, no. 6, pp. 747–793, 1993. View at Publisher · View at Google Scholar · View at Scopus
  53. G. B. Bartley, V. Fatourechi, E. F. Kadrmas et al., “Clinical features of Graves’ ophthalmopathy in an incidence cohort,” American Journal of Ophthalmology, vol. 121, no. 3, pp. 284–290, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. D. H. Khoo, P. H. Eng, S. C. Ho et al., “Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels,” Thyroid, vol. 10, no. 12, pp. 1093–1100, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Kamijo, K. Ishikawa, and M. Tanaka, “Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith,” Endocrine Journal, vol. 52, no. 5, pp. 525–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Pinchera, P. Liberti, E. Martino et al., “Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies,” The Journal of Clinical Endocrinology & Metabolism, vol. 29, no. 2, pp. 231–238, 1969. View at Publisher · View at Google Scholar
  57. Y. Aizawa, K. Yoshida, N. Kaise et al., “Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves’ disease,” Clinical Endocrinology, vol. 42, no. 5, pp. 517–522, 1995. View at Publisher · View at Google Scholar
  58. Y. Takamura, K. Nakano, T. Uruno et al., “Changes in serum TSH receptor antibody (TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy,” Endocrine Journal, vol. 50, no. 5, pp. 595–601, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. A. K. Eckstein, M. Plicht, H. Lax et al., “Clinical results of anti-inflammatory therapy in Graves’ ophthalmopathy and association with thyroidal autoantibodies,” Clinical Endocrinology, vol. 61, no. 5, pp. 612–618, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Y. Goh, S. C. Ho, L. L. Seah, K. S. Fong, and D. H. C. Khoo, “Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease,” Clinical Endocrinology, vol. 60, no. 5, pp. 600–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Kuś, K. Szymański, B. Jurecka-Lubieniecka et al., “Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves’ ophthalmopathy,” Journal of Human Genetics, vol. 62, no. 3, pp. 373–377, 2017. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Huang, Q. Luo, H. Yang, and Y. Mao, “Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy,” Investigative Ophthalmology & Visual Science, vol. 55, no. 8, pp. 4935–4943, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. R. H. Song, Q. Qin, X. Wang et al., “Differential cytokine expression detected by protein microarray screening in peripheral blood of patients with refractory Graves’ disease,” Clinical Endocrinology, vol. 84, no. 3, pp. 402–407, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Nowak, L. Siemińska, J. Karpe, B. Marek, B. Kos-Kudła, and D. Kajdaniuk, “Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy,” Journal of Endocrinological Investigation, vol. 39, no. 1, pp. 63–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Li, Y. Qi, X. Ma et al., “Chemokine (C-C motif) ligand 20, a potential biomarker for Graves’ disease, is regulated by osteopontin,” PLoS One, vol. 8, no. 5, article e64277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Wei, M. Guan, Y. Qin et al., “Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy,” Endocrine Journal, vol. 61, no. 11, pp. 1087–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Mysliwiec, I. Palyga, A. Nikolajuk, A. Kowalska, and M. Gorska, “Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy,” Endokrynologia Polska, vol. 63, no. 2, pp. 92–96, 2012. View at Google Scholar
  68. C. Liang, W. Du, Q. Dong et al., “Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Graves’ disease,” Experimental and Therapeutic Medicine, vol. 9, no. 3, pp. 925–930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. H. T. Celik, S. Abusoglu, S. F. Burnik et al., “Increased serum interleukin-33 levels in patients with Graves’ disease,” Endocrine Regulations, vol. 47, no. 2, pp. 57–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Nowak, T. Wielkoszyński, B. Kos-Kudła et al., “The blood concentration of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with active thyroid-associated orbitopathy before and after methylprednisolone treatment,” Endokrynologia Polska, vol. 58, no. 6, pp. 487–491, 2007. View at Google Scholar
  71. M. Ventura, M. Melo, and F. Carrilho, “Selenium and thyroid disease: from pathophysiology to treatment,” International Journal of Endocrinology, vol. 2017, Article ID 1297658, 9 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  72. J. J. Khong, R. F. Goldstein, K. M. Sanders et al., “Serum selenium status in Graves’ disease with and without orbitopathy: a case–control study,” Clinical Endocrinology, vol. 80, no. 6, pp. 905–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Reza, A. Shaukat, T. M. Arain, Q. S. Riaz, and M. Mahmud, “Expression of osteopontin in patients with thyroid dysfunction,” PLoS One, vol. 8, no. 2, article e56533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Esteghamati, O. Khalilzadeh, Z. Mobarra et al., “Association of CTLA-4 gene polymorphism with Graves’ disease and ophthalmopathy in Iranian patients,” European Journal of Internal Medicine, vol. 20, no. 4, pp. 424–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Frydecka, J. Daroszewski, K. Suwalska et al., “CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves’ disease in a Polish population of the Lower Silesian region,” Archivum Immunologiae et Therapiae Experimentalis, vol. 52, no. 5, pp. 369–374, 2004. View at Google Scholar
  76. O. Khalilzadeh, S. Noshad, A. Rashidi, and A. Amirzargar, “Graves ophthalmopathy: a review of immunogenetics,” Current Genomics, vol. 12, no. 8, pp. 564–575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Pawlowski, J. Mysliwiec, M. Mrugacz et al., “Elevated percentage of HLA-DR+ and ICAM-1+ conjunctival epithelial cells in active Graves’ orbitopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 4, pp. 641–645, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. V. Stenszky, L. Kozma, C. Balazs, and N. R. Farid, “HLA-DR associations with Graves’ disease in eastern Hungary,” Clinical and Investigative Medicine, vol. 6, no. 3, pp. 181–184, 1983. View at Google Scholar
  79. A. Czarnywojtek, K. Komar-Rychlicka, M. Zgorzalewicz-Stachowiak et al., “Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption: a 6-month follow-up,” Polskie Archiwum Medycyny Wewnętrznej, vol. 126, no. 10, pp. 746–753, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Czarnywojtek, M. Zgorzalewicz-Stachowiak, B. Budny et al., “The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves’ ophthalmopathy,” Neuro Endocrinology Letters, vol. 34, no. 3, pp. 241–248, 2013. View at Google Scholar
  81. J. R. M. Martins, R. P. Furlanetto, L. M. Oliveira et al., “Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy,” Clinical Endocrinology, vol. 60, no. 6, pp. 726–733, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. C. C. Tsai, C. Y. Cheng, C. Y. Liu et al., “Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution,” Eye, vol. 23, no. 8, pp. 1725–1730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Planck, B. Shahida, H. Parikh et al., “Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy,” Thyroid, vol. 24, no. 10, pp. 1524–1532, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. D. G. Ezra, J. Krell, G. E. Rose, M. Bailly, J. Stebbing, and L. Castellano, “Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy,” Journal of Clinical Pathology, vol. 65, no. 7, pp. 608–613, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. L. van Steensel, H. Hooijkaas, D. Paridaens et al., “PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves’ ophthalmopathy patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, pp. E944–E953, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. L. van Steensel, D. Paridaens, M. van Meurs et al., “Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 3, pp. E400–E408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Virakul, L. van Steensel, V. A. S. H. Dalm, D. Paridaens, P. M. van Hagen, and W. A. Dik, “Platelet-derived growth factor: a key factor in the pathogenesis of Graves’ ophthalmopathy and potential target for treatment,” European Thyroid Journal, vol. 3, no. 4, pp. 217–226, 2014. View at Publisher · View at Google Scholar
  88. L. van Steensel, D. Paridaens, B. Schrijver et al., “Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy,” Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3091–3098, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Virakul, V. A. S. H. Dalm, D. Paridaens et al., “Platelet-derived growth factor-BB enhances adipogenesis in orbital fibroblasts,” Investigative Ophthalmology & Visual Science, vol. 56, no. 9, pp. 5457–5464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. H. S. Lim, K. O. Back, H. J. Kim, Y. H. Choi, Y. M. Park, and K. H. Kook, “Hyaluronic acid induces COX-2 expression via CD44 in orbital fibroblasts from patients with thyroid-associated ophthalmopathy,” Investigative Ophthalmology & Visual Science, vol. 55, no. 11, pp. 7441–7450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Pawlowski, N. Wawrusiewicz-Kurylonek, A. Eckstein et al., “Disturbances of modulating molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) mRNA expressions in the orbital tissue from patients with severe Graves’ ophthalmopathy,” Mediators of Inflammation, vol. 2015, Article ID 340934, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Kim and M. P. Hatton, “The role of genetics in Graves’ disease and thyroid orbitopathy,” Seminars in Ophthalmology, vol. 23, no. 1, pp. 67–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Cai and R. Wei, “Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy,” Endocrine, vol. 44, no. 1, pp. 140–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Matheis, F. H. Grus, M. Breitenfeld et al., “Proteomics differentiate between thyroid-associated orbitopathy and dry eye syndrome,” Investigative Ophthalmology & Visual Science, vol. 56, no. 4, pp. 2649–2656, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Matheis, M. Lantz, F. H. Grus et al., “Proteomics of orbital tissue in thyroid-associated orbitopathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 12, pp. E1523–E1530, 2015. View at Publisher · View at Google Scholar · View at Scopus